Ortec International, a company focused on development and commercialization of products applicable to regenerative medicine and stem cell therapy, June 1 announced that it has received notification from the U.S. patent office that the claims of its patent application on "Novel Haptotactic Peptides," related to its Haptides technology platform, have been allowed. The patent incorporating these claims is expected to be issued by the end of this year. Ortec International (http://www.efcg.net/NewsRelease.asp?NewsID=1248)